IL222197A0 - CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY - Google Patents

CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY

Info

Publication number
IL222197A0
IL222197A0 IL222197A IL22219712A IL222197A0 IL 222197 A0 IL222197 A0 IL 222197A0 IL 222197 A IL222197 A IL 222197A IL 22219712 A IL22219712 A IL 22219712A IL 222197 A0 IL222197 A0 IL 222197A0
Authority
IL
Israel
Prior art keywords
species
cross
single chain
chain antibody
bispecific single
Prior art date
Application number
IL222197A
Other languages
English (en)
Original Assignee
Peter Kufer
Amgen Res Munich Gmbh
Ralf Lutterbuese
Matthias Klinger
Susanne Hausmann
Carola Steiger
Tobias Raum
Patrick Hoffmann
Roman Kischel
Evelyne Schaller
Susanne Mangold
Petra Fluhr
Doris Rau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter Kufer, Amgen Res Munich Gmbh, Ralf Lutterbuese, Matthias Klinger, Susanne Hausmann, Carola Steiger, Tobias Raum, Patrick Hoffmann, Roman Kischel, Evelyne Schaller, Susanne Mangold, Petra Fluhr, Doris Rau filed Critical Peter Kufer
Publication of IL222197A0 publication Critical patent/IL222197A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL222197A 2010-04-01 2012-09-27 CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY IL222197A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32005210P 2010-04-01 2010-04-01
PCT/EP2011/055104 WO2011121110A1 (en) 2010-04-01 2011-04-01 CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY

Publications (1)

Publication Number Publication Date
IL222197A0 true IL222197A0 (en) 2012-12-31

Family

ID=44198856

Family Applications (1)

Application Number Title Priority Date Filing Date
IL222197A IL222197A0 (en) 2010-04-01 2012-09-27 CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY

Country Status (17)

Country Link
US (1) US9587036B2 (enExample)
EP (1) EP2552964B1 (enExample)
JP (1) JP6153862B2 (enExample)
KR (1) KR101799922B1 (enExample)
CN (2) CN103025759A (enExample)
AR (1) AR080868A1 (enExample)
AU (1) AU2011234443B2 (enExample)
BR (1) BR112012024964B1 (enExample)
CA (1) CA2793139C (enExample)
IL (1) IL222197A0 (enExample)
MX (1) MX348360B (enExample)
NZ (1) NZ602209A (enExample)
RU (1) RU2617942C2 (enExample)
SG (1) SG183937A1 (enExample)
TW (1) TWI653333B (enExample)
WO (1) WO2011121110A1 (enExample)
ZA (1) ZA201206572B (enExample)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037838A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
SG194399A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
WO2010037837A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
ME02485B (me) * 2008-10-01 2017-02-20 Amgen Res Munich Gmbh Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
SG190726A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
US20140161800A1 (en) 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
UA115402C2 (uk) * 2011-05-21 2017-10-25 Макродженікс, Інк. Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
GB201303308D0 (en) * 2013-02-25 2013-04-10 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
ES2776706T3 (es) * 2013-07-05 2020-07-31 Genmab As Anticuerpos contra CD3 humanizados o quiméricos
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
JP6449295B2 (ja) 2013-12-17 2019-01-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
TN2017000532A1 (en) 2014-03-28 2019-04-12 Xencor Inc Bispecific antibodies that bind to cd38 and cd3.
WO2015156268A1 (ja) 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
CN106459954A (zh) 2014-05-13 2017-02-22 中外制药株式会社 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
CN106661119A (zh) 2014-07-01 2017-05-10 辉瑞公司 双特异性异二聚化双抗体及其用途
US9212225B1 (en) 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
CN107108738A (zh) 2014-07-25 2017-08-29 西托姆克斯治疗公司 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
WO2016016859A1 (en) * 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
EA201790342A1 (ru) 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
BR112017011092A2 (pt) 2014-11-26 2017-12-26 Xencor Inc anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN107406512A (zh) 2014-11-26 2017-11-28 Xencor公司 结合cd3和cd38的异二聚体抗体
HK1252158A1 (zh) * 2015-05-01 2019-05-17 Genentech, Inc. 掩蔽抗cd3抗体和使用方法
CA2985125A1 (en) * 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
JP6841754B2 (ja) * 2015-05-13 2021-03-10 中外製薬株式会社 多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
AU2016271113B2 (en) 2015-05-29 2022-09-08 Amphivena Therapeutics, Inc. Methods of using bispecific CD33 and CD3 binding proteins
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
JP6925278B2 (ja) 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
CN108699136B (zh) * 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
PL3411404T3 (pl) 2016-02-03 2023-02-13 Amgen Research (Munich) Gmbh Konstrukty dwuswoistych przeciwciał wobec PSMA i CD3 angażujących komórki T
US11414497B2 (en) 2016-04-13 2022-08-16 Orimabs Ltd. Anti-PSMA antibodies and use thereof
EP3468586B1 (en) 2016-06-14 2024-08-07 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
KR20240044520A (ko) * 2016-09-14 2024-04-04 테네오원, 인코포레이티드 Cd3 결합 항체
US10689461B2 (en) 2016-09-15 2020-06-23 Novimmune Sa Antibody dual display dual compositions and methods of use thereof
IL265800B2 (en) * 2016-10-11 2023-10-01 Agenus Inc Anti-LAG-3 antibodies and methods of using them
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP4215548A1 (en) 2016-12-21 2023-07-26 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
TWI676681B (zh) * 2017-03-29 2019-11-11 臺北醫學大學 具抗原專一性的t細胞及其用途
CN117866097A (zh) 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CN118146370A (zh) 2017-06-20 2024-06-07 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
TWI811229B (zh) 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
AU2018347607B2 (en) 2017-10-14 2025-08-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
WO2019094637A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
ES2986967T3 (es) 2018-02-08 2024-11-13 Dragonfly Therapeutics Inc Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
MA51793A (fr) 2018-02-08 2020-12-16 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
BR112020016939A2 (pt) 2018-02-20 2020-12-15 Dragonfly Therapeutics, Inc. Proteínas de ligação multiespecíficas que se ligam a cd33, nkg2d, e cd16 e métodos de uso
CN120399075A (zh) 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
US11976131B2 (en) * 2018-07-31 2024-05-07 Heidelberg Pharma Research Gmbh Humanized antibodies against PSMA
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
SG11202100883SA (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
SG11202109406TA (en) 2019-03-01 2021-09-29 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
CN110156890B (zh) * 2019-04-09 2021-02-02 苏州大学 Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
EP3983438A1 (en) 2019-06-14 2022-04-20 TeneoBio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
CA3146341A1 (en) * 2019-07-30 2021-02-04 Aaron L. Kurtzman Bispecific anti lrrc15 and cd3epsilun antibudies
TWI897903B (zh) 2019-12-13 2025-09-21 美商建南德克公司 抗ly6g6d抗體及其使用方法
BR112022013725A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Formulações para agentes terapêuticos proteicos
IL294461A (en) 2020-01-13 2022-09-01 Aptevo Res & Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
EP4240766A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
AU2021374592A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
PE20231860A1 (es) 2020-11-06 2023-11-21 Amgen Inc Moleculas de union a antigeno biespecificas con multiples dianas de selectividad aumentada
EP4259193A4 (en) * 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
WO2022125583A1 (en) * 2020-12-09 2022-06-16 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
AU2021443318A1 (en) 2021-04-30 2023-09-07 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
AU2022269312A1 (en) 2021-05-06 2023-10-19 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
EP4341291A1 (en) 2021-05-21 2024-03-27 Aptevo Research and Development LLC Dosing regimens for protein therapeutics
CN118946583A (zh) 2022-03-21 2024-11-12 美国安进公司 用t细胞接合分子治疗前列腺癌的联合治疗方法
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
CA2164088C (en) 1993-06-07 2005-06-14 Gary J. Nabel Plasmids suitable for gene therapy
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US7435549B1 (en) 1997-11-17 2008-10-14 Micromet Ag Method of identifying binding site domains that retain the capacity of binding to an epitope
WO1999054440A1 (en) 1998-04-21 1999-10-28 Micromet Gesellschaft Für Biomedizinische Forschung Mbh CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
RU2179862C1 (ru) * 2000-12-26 2002-02-27 Общество с ограниченной ответственностью Научно-производственный центр "МедБиоСпектр" Лекарственное средство для предотвращения отторжения трансплантата, моноклональное антитело к cd3-антигену т-лимфоцитов человека, гибридома и способ лечения больных, имеющих реакцию острого отторжения трансплантата после пересадки почки
DK1629011T3 (da) 2003-05-31 2010-05-03 Micromet Ag Humane anti-humane-DC3-bindingsmolekyler
MXPA06004035A (es) * 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
MX2007009878A (es) 2005-02-18 2007-10-03 Medarex Inc Anticuerpos monoclonales para antigeno de membrana especifica para prostata (amep).
EP1726650A1 (en) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
US20070065437A1 (en) 2005-09-12 2007-03-22 Greg Elson Anti-CD3 antibody formulations
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
WO2007059190A2 (en) * 2005-11-14 2007-05-24 Psma Development Company, Llc. Compositions of and methods of using stabilized psma dimers
WO2008119566A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
US20100150918A1 (en) * 2007-04-03 2010-06-17 Micromet Ag Cross-species-specific binding domain
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
CA2695382A1 (en) * 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health Of Human Services, National Institutes Of A fold-back diabody diphtheria toxin immunotoxin and methods of use
JP4970211B2 (ja) 2007-10-18 2012-07-04 ヘキサゴン・メトロジー株式会社 ３次元形状測定器
WO2010037837A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Bispecific single chain antibodies with specificity for high molecular weight target antigens
SG194399A1 (en) * 2008-10-01 2013-11-29 Amgen Res Munich Gmbh Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
WO2010037838A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
ME02485B (me) 2008-10-01 2017-02-20 Amgen Res Munich Gmbh Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću

Also Published As

Publication number Publication date
WO2011121110A1 (en) 2011-10-06
JP2013528569A (ja) 2013-07-11
KR101799922B1 (ko) 2017-11-21
RU2012143519A (ru) 2014-05-10
RU2617942C2 (ru) 2017-04-28
BR112012024964B1 (pt) 2021-05-25
NZ602209A (en) 2014-08-29
US9587036B2 (en) 2017-03-07
AU2011234443B2 (en) 2014-05-22
CA2793139A1 (en) 2011-10-06
MX2012011405A (es) 2013-01-29
AR080868A1 (es) 2012-05-16
MX348360B (es) 2017-06-07
KR20130088013A (ko) 2013-08-07
US20130129730A1 (en) 2013-05-23
JP6153862B2 (ja) 2017-06-28
EP2552964A1 (en) 2013-02-06
ZA201206572B (en) 2019-10-30
TWI653333B (zh) 2019-03-11
AU2011234443A1 (en) 2012-09-27
EP2552964B1 (en) 2019-10-02
BR112012024964A2 (pt) 2017-07-18
CA2793139C (en) 2023-08-08
TW201134942A (en) 2011-10-16
CN107090044A (zh) 2017-08-25
CN103025759A (zh) 2013-04-03
SG183937A1 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
IL222197A0 (en) CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY
IL257712B (en) Antibodies that bind csf1r
ZA201101067B (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
IL214885A0 (en) Bispecific anti-erbb-1/anti-c-met antibodies
IL215062A0 (en) Bispecific anti-erbb-3/anti-c-met antibodies
PL2581113T3 (pl) Przeciwciało anty-tim-3
HUE038962T2 (hu) DLL3-ellenes antitest
IL220404A (en) Antiseptic antibodies
ZA201209004B (en) Anti-fgfr2 antibodies
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
PT2603528T (pt) Anticorpos glicosilados em fab
GB201020738D0 (en) Antibodies
ZA201302459B (en) Antibodies
GB201002238D0 (en) Antibodies
GB201007957D0 (en) Antibody
GB201014527D0 (en) Chain
GB201017780D0 (en) Antibody
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed